A Study to Examine the Long Term Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects
Completed
AstraZeneca
Phase 2
2005-09-01
This is a long term extension to study 137OB-201 which is designed to examine the effect of
pramlintide on body weight and its safety and tolerability in obese subjects.
An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes
Completed
AstraZeneca
2005-09-01
This is an open label, observational study designed to collect data that characterize the use
of SYMLIN following the introduction of the medication into the marketplace. Health care
providers and subjects selected for study participation are intended to be representative of
those providers prescribing, and subjects receiving, SYMLIN therapy.
A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes
Completed
AstraZeneca
Phase 4
2005-10-01
The purpose of this study is to evaluate the efficacy and safety of adding Symlin to an
established regimen of insulin glargine in subjects with type 2 diabetes who are not
achieving glycemic targets.
A Study to Evaluate Symlin in Adolescent Subjects With Type 1 Diabetes Mellitus
Completed
AstraZeneca
Phase 2
2006-04-01
This study will be the first evaluation of Symlin in adolescent subjects with type 1 diabetes
mellitus and is designed to evaluate the blood levels (pharmacokinetics), biochemical and
physiological effects (pharmacodynamics), and safety and tolerability of Symlin in these
subjects.
A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects
Completed
AstraZeneca
Phase 2
2006-11-01
This study will examine the safety, tolerability, and body weight effect of subcutaneous
pramlintide alone and in various combinations with the oral antiobesity agents sibutramine or
phentermine in overweight and obese subjects.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
